2020/10/20 – CRI Report

Research Report on Chinese Deproteinized Calf Blood Extractives Market 2020-2024

admin — Tue, 20 Oct 2020 02:29:52 +0000

Description
Deproteinized Calf Blood Extractives, is a drug that improves the energy metabolism of cells, has aroused a wide concern at home and abroad after years of clinical application because of its prominent curative effect on the nervous system. At present, the clinical applications mainly include cerebral and nervous system diseases, vascular diseases, ulcer diseases and burns.
According to CRI’s research, the global growth of patented nervous system drugs is slowing down. The drugs used to treat cranial nerve and cerebral circulation systems are experiencing a market downturn. However, the market performance is quite different in China. In recent years, the drug demand from neurology departments of Chinese hospitals is growing continuously with the rapid development of the pathogenesis of common neurological diseases and clinical pharmacology. Deproteinized Calf Blood Extractives is a big variety and a pillar nervous system drug in clinical applications in China.
According to CRI’s research, the sales value of Deproteinized Calf Blood Extractives reached CNY146.45 million in 2019, the CAGR was -24.7% in 2015 to 2019. In recent years, the main reason for the decline in sales of Deproteinized Calf Blood Extractives in the Chinese market is the continuous decline in sales of injections, and the sales of other dosage forms have an upward trend. The market was dominated by Shenyang Xingqi Pharmaceutical Co., Ltd., Harbin Sanctity Pharmaceutical Co., Ltd., Jilin Connell Pharmaceutical Co., Ltd., Wuhan Humanwell Pharmaceutical Co., Ltd., etc., with CR5 reaching over 90%. Shenyang Xingqi Pharmaceutical Co., Ltd. captured the biggest market share, whose market share exceeded 28.2% by sales value in 2019.
According to CRI’s research, the sales of Deproteinized Calf Blood Extractives injections in the Chinese market are showing a declining trend, but the sales of other dosage forms, such as gels, are rising rapidly. It is expected that the overall sales of Deproteinized Calf Blood Extractives in China may rebound in the next few years.

Topics Covered:
-Development environment of the Chinese Deproteinized Calf Blood Extractives market
-Market Size of the Chinese Deproteinized Calf Blood Extractives market 2015-2019
-Market Size of Deproteinized Calf Blood Extractives by regions in China 2015-2019
-Market Share of major manufacturers of Deproteinized Calf Blood Extractives in China 2015-2019
-Prices of major manufacturers of Deproteinized Calf Blood Extractives in China 2019-2020
-Forecast on the Chinese Deproteinized Calf Blood Extractives market 2020-2024

The post Research Report on Chinese Deproteinized Calf Blood Extractives Market 2020-2024 first appeared on CRI Report.

Research Report on China’s New Energy Vehicle Drive Motor Industry, 2020-2024

admin — Tue, 20 Oct 2020 02:29:47 +0000

Description
With government support and technological progress, the global electric vehicle market is developing rapidly. The production volume of global electric vehicle increased rapidly from only 68,000 units in 2011 to 2.19 million units in 2019, the CAGR was 54.4% in 2011 to 2019. The performance of the US, European and Chinese markets is excellent. With the rapid development of the global electric vehicle industry, the new energy vehicle’s drive motor industry is also growing rapidly.

As one of the three core components of the new energy vehicle, the drive motor is mainly composed of the stator, the rotor, the housing, the connector, the resolver, etc. The drive motor and the controller constitute the core system of the new energy vehicle, i.e. the drive motor system, whose performance determines the main performance indicators such as a vehicle’s climbing performance, acceleration, and maximum speed. At present, the driving motors used in new energy vehicles mainly include DC motors, AC motors and switched reluctance motors. Permanent magnet synchronous motors take up the largest share of the Chinese motor market, followed by AC asynchronous motors.
In recent years, the Chinese government is vigorously advocating and has introduced a series of policies for the development of new energy vehicles, which booms the new energy vehicle industry. According to CRI’s research, from 2015 to 2019, the production and sales volume of new energy vehicles (electric vehicles) in China ranked the first in the world for five consecutive years. As a result, the production volume of China’s new energy vehicle drive motors was only 72,000 in 2014 and increased to 1.33 million in 2018, with a CAGR of 107% from 2014 to 2018. In 2019, due to the decline in the production and sales of new energy vehicles in China, the production volume of new energy vehicle drive motors also dropped to 1.24 million.
The unprecedented market prospect has led to a sharp increase in the number of industry participants and increasingly fierce market competition. The electric vehicle drive motor manufacturers in China mainly include the enterprises that have experience in the manufacture of traditional automobiles and auto parts, for example, BYD and BAIC Group; the enterprises that have experience in the manufacture of motors for other sectors, for example, Zhongshan Broad-Ocean Motor Co., Ltd. and Jiangxi Special Electric Motor Co., Ltd.; and the motor enterprises established for new energy vehicles, for example, Shenzhen Greatland Electrics Inc. and Shanghai Dajun Technologies Inc. The costs of driving motors account for a high proportion.
The development of new energy vehicles (electric vehicles) is the fundamental solution to reducing environmental pollution and the reliance on fossil fuels.
According to CRI’s research, due to the adverse effects of the COVID-19 epidemic, global sales volume of new energy vehicles will likely decline from 2020 to 2021, but they will start to grow again in 2022. From 2022 to 2024, the global and Chinese electric vehicle production will continue to rise rapidly, thus creating a broad market for the drive motor industry.
The trend of China’s new energy vehicle market is basically the same as that of the global market. It will decline from 2020 to 2021 but will start to grow again in 2020. For manufacturers of new energy vehicle drive motors, the market growth rate will be low or even slightly decreased from 2020 to 2021, but it will grow rapidly from 2022.

Topics Covered:
– Development environment of China’s new energy vehicle drive motor industry
– Supply of and demand for new energy vehicle drive motors in China
– Major electric vehicle drive motor manufacturers in China
– Competition in China’s electric vehicle drive motor industry
– Production cost trend and price trend of electric vehicle drive motors in China
– Major driving forces and market opportunities for China’s electric vehicle drive motor industry from 2020 to 2024
– Forecast on the supply of and demand for new energy vehicle’s drive motor in China from 2020 to 2024

The post Research Report on China’s New Energy Vehicle Drive Motor Industry, 2020-2024 first appeared on CRI Report.

Investigation Report on Chinese Rituximab Market, 2020-2024

admin — Tue, 20 Oct 2020 02:29:44 +0000

Description
Rituximab (Roche’s trade name: MabThera/Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc. In Sep 2019, FDA approved Roche’s rituximab in combination with glucocorticoids for treating granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) disorders.
The global sales of rituximab have been very mature. In the year of 2019, Rituximab recorded a revenue of US$6.7 billion. The drug was mostly used for tumor treatment.
In China, Roche’s Rituximab is mainly used to treat non-Hodgkin lymphoma. As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin’s disease in China. The incidence of non-Hodgkin’s lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 60 cases per 1 million people in 2019.
On December 10, 2019, Roche announced that its Rituxan/MabThera, (rituximab) has been formally approved by the National Medical Products Administration (NMPA) of China for the initial treatment of follicles Monotherapy for patients with lymphoma (FL) who have achieved complete or partial remission after rituximab combined with chemotherapy, and combined treatment with fludarabine and cyclophosphamide (FC) for previously untreated or relapsed/refractory Patients with chronic lymphocytic leukemia (CLL).
According to CRI’s market research, in 2019, the sales value of Rituximab reached CNY1.42 billion(US$206 million) in China.
According to CRI’s market research, by the end of 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech.
However, starting in 2019, Shanghai Henlius Biotech, Inc.’s rituximab (trade name: Hanlikang) began to be listed on the Chinese market. According to sales in 2019, Roche and Genentech’s rituximab products accounted for approximately 98% of the Chinese market, and the corporate market share was occupied by Shanghai Henlius Biotech, Inc.
According to CRI’s market research, it is expected that with the launch of more domestic rituximab products in China, the market share of Roche and Genentech will continue to decline in 2020-2024. But for a long period of time, Roche and Genentech will still occupy the major market share of rituximab in China.

Topics Covered:
-Development environment of Chinese Rituximab market
-Sales value and volume of Rituximab in China 2015-2019
-Sales value and volume of Rituximab in Different Regions of China 2015-2019
-Prices of Rituximab in China 2015-2019
-Prices of Roche’s Rituximab(MabThera/ Rituxan) in Different Regions of China 2015-2019
-Prices of Shanghai Henlius Biotech, Inc.’s Rituximab(Hanlikang) in Different Regions of China 2015-2019
-Progress of generic Rituximab in China
-Prospects of Chinese Rituximab Market, 2020-2024

The post Investigation Report on Chinese Rituximab Market, 2020-2024 first appeared on CRI Report.

Investigation Report on Sevoflurane in China, 2020-2024

admin — Tue, 20 Oct 2020 02:29:44 +0000

Description
Sevoflurane is an inhaled general anesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage.
According to CRI’s analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States. In 2007 and 2008, Chinese government approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China. Gradually, domestic sevoflurane dominates the Chinese market.
As the environmental pollution intensifies and the population ages, the demand for medical services is rapidly rising. The hospitalization increased from 115 million in 2008 to 266 million in 2019, with the CAGR up to 7.9%. Among them, one quarter of patients was hospitalized for surgery. The increasing amount of surgery boosts the demand for narcotic drugs.
According to CRI’s research, sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 723.4 million in 2019 and the CAGR is about 19.8% in 2007 to 2019.
According to CRI’s market research, the major market share holders in China are Shanghai Hengrui Pharmaceutical Co., Ltd., Maruishi, Baxter and Lunan Better Pharmaceutical Co., Ltd. In terms of sales value, Shanghai Hengrui Pharmaceutical holds the biggest market occupancy, which was about 66.4% in 2019.
According to CRI’s market research, in 2020, due to the COVID-19 epidemic, the number of surgeries in Chinese hospitals will decrease, so the sales of sevoflurane will also decrease accordingly. It is expected that from 2021 to 2024, the demand for sevoflurane in the Chinese market will show a recovery growth.

Topics Covered:
-Indication of sevoflurane
-Sales volume and value of sevoflurane in China 2015-2019
-Sales volume and value of sevoflurane in different regions of China 2015-2019
-Major sevoflurane manufacturers in the Chinese market
-Competition pattern of sevoflurane in China
-Sale price of sevoflurane in China
-Sale price of sevoflurane by manufacturers and regions in China
-Prospects of sevoflurane in China 2020-2024
-The impact of the COVID-19 outbreak on China’s sevoflurane market

The post Investigation Report on Sevoflurane in China, 2020-2024 first appeared on CRI Report.

Research Report on China Express Delivery Industry, 2020-2024

admin — Tue, 20 Oct 2020 02:29:44 +0000

From 2015 to 2020, the frequency of online shopping applications of Chinese Internet users increased from 56.00% to 79.7%. Online shopping has become one of the important daily activities of Chinese residents.

With the development of China’s economy, especially e-commerce industry, the volume of express delivery kept increasing from 20.67 billion in 2015 to 63.52 billion in 2019, indicating that China’s express delivery industry is booming.

With the outbreak of COVID-19 in China in early 2020, due to the launch of lockdown by multiple local governments in China, China’s express delivery industry has been greatly affected from January to February 2020.

According to CRI’s market research, the total volume of China’s express delivery from January to February 2020 is about 6.54 billion, a year-on-year decrease of about 10%. From January to February 2020, the number of express delivery from China to foreign countries reached 188.8 million, a year-on-year increase of 5.3%.

Since March 2020, the epidemic in China has gradually been brought under control, and more and more Chinese residents have chosen to shop online, which has gradually increased the volume of express delivery in China. From January to August 2020, China’s express delivery volume totaled 48.05 billion, a year-on-year increase of 25.4%. The outbreak of COVID-19 has promoted the growth of China’s express delivery industry to a certain extent.

B2B E-Commerce Market to Surge at 16.5% CAGR, which is anticipated to reach USD 28.5 trillion by 2030

According to CRI’s market research, Chinese express delivery companies can be classified into four types: 1) Foreign-funded express delivery companies, such as DHL; 2) State-owned express delivery companies, such as EMS; 3) Large private express delivery companies, such as S.F. Express, STO Express; and 4) other small private express delivery companies.

Top 5 express delivery players in China usually refer to S.F. Express, YTO Express, ZTO Express, Yunda Express and STO Express.
According to CRI’s market research, two of the most important costs in express delivery industry is transportation and labor cost. On the one hand, the price of gasoline and diesel oil is in a downward trend soon, so the cost of express industry is facing a downward trend.

In addition, due to the large fluctuation of oil price, the cost of express industry will be affected to some extent; on the other hand, labor costs are measured by wages, showing a slow upward trend. It means that the express industry is facing high labor costs.In recent years, the price of each express company has been equal. From the time dimension, the price level is decreasing year by year.

The reasons for the price changes of express delivery in China in 2015-2019 can be explained from two perspectives: the booming online shopping and mobile business in China; gradually formed scale effect, which saves part of the cost and is able to maintain the price stability.

With the maturity of the express industry, various express companies are competing in different ways, and the price gap is expected to be widened. In addition, due to the rising trend of labor and other costs, the overall average price of express delivery will slightly rise.

According to CRI’s market research, although the COVID -19 epidemic will not be completely over in the short term, the epidemic has not caused a significant adverse impact on the express delivery industry. To a certain extent, the existence of the epidemic has promoted the demand for the express delivery industry in the Chinese market.

Global Managed Security Services Market by deployment type (On premises and on cloud); by organization(Small and medium enterprise and large enterprise); by application (BFSI, Retail & E-commerce, Government, Healthcare, IT & Telecom, Construction and Others); and Region –Analysis of Market Size, Share & Trends for 2016 – 2019 and Forecasts to 2029

Topics Covered in Research Report on China Express Delivery Industry, 2020-2024

– Economic Environment of Express Delivery Industry in China 2015-2020
– Policies in Express Delivery Industry in China
– Analysis of Supply and Demand in Express Delivery Industry in China
– International and domestic express delivery in China
– Analysis of Market Competition in Express Delivery Industry in China
– Analysis of Major Companies in Express Delivery Industry in China
– Analysis of Costs in Express Delivery Industry in China
– Price Trend of Express Delivery Services in China
– Driving Forces and Opportunities in Express Delivery Industry in China
– Unfavorable Factors in Express Delivery Industry in China
– Forecast on Supply and Demand in Express Delivery Industry in China 2020-2024
– The impact of COVID-19 on international express delivery and China’s domestic express delivery industry

The post Research Report on China Express Delivery Industry, 2020-2024 first appeared on CRI Report.

Investigation Report on Chinese Hydroxychloroquine(HCQ) Market, 2020-2024

admin — Tue, 20 Oct 2020 02:29:43 +0000

Description
Hydroxychloroquine(HCQ) is an antimalarial drug. It treats malaria by killing the parasites that cause the disease. Hydroxychloroquine was listed in the United States in 1955, and the original research drug manufacturer was Sanofi. Hydroxychloroquine has been listed in Canada, France, Germany, Australia, China, Japan and other countries, and many companies worldwide have produced generic drugs of hydroxychloroquine. The indications for hydroxychloroquine include malaria, rheumatoid arthritis, lupus erythematosus, etc.
According to CRI, in 2019, the global production volume of hydroxychloroquine was approximately 300 tons. Among them, India produced about 110 tons, ranking first. The total production volume in Europe is about 80 tons, of which Sanofi’s production is about 60 tons, and Novartis’s Sandoz production is about 20 tons. Hydroxychloroquine produced in Europe is mainly sold to Europe and Asia. China’s production is about 55 tons, most of which are sold in China. In 2020, China exported about 20 tons of hydroxychloroquine APIs. The hydroxychloroquine preparations on the global market are basically hydroxychloroquine sulfate preparations. In 2019, the world’s most important hydroxychloroquine market was the United States, which consumed approximately 90 tons of hydroxychloroquine APIs, and the main source of imports was India. India is the world’s second largest market, consuming approximately 60 tons of APIs. The Chinese market consumes approximately 35 tons of APIs.
It is not fully understood how this drug works to treat lupus erythematosus or rheumatoid arthritis. However, it is believed that this drug affects how your immune system works, which may be a benefit in lupus erythematosus and rheumatoid arthritis.
On March 28, 2020, FDA issued an EUA to allow hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile (SNS) to be distributed and used for hospitalized COVID-19 patients. An EUA allows for an unapproved drug to be prescribed in limited and controlled ways during an emergency such as a pandemic.
There is a lot of controversy over whether hydroxychloroquine can prevent, treat, or cure COVID-19, the illness caused by the novel coronavirus. Some small studies in China and Europe were initially promising, however, other studies have found that hydroxychloroquine offers no benefit or may even be harmful to patients infected with the coronavirus. There are many more studies underway, but the best available evidence suggests that hydroxychloroquine is not effective in the treatment and prevention of COVID-19, and the potential benefits of the drug do not outweigh the known and potential risks. As a result, on June 15, 2020, the FDA has revoked their earlier issue of an Emergency Use Authorization (EUA) for hydroxychloroquine.
According to CRI’s market research, as of the end of 2020, only two companies in the Chinese market have been approved for hydroxychloroquine, namely Sanofi, the original research drug manufacturer of hydroxychloroquine, and Shanghai Zhongxi Pharmaceutical Co., Ltd., a generic drug manufacturer.
According to CRI’s market research, in 2019, the sales value of Hydroxychloroquine reached CNY340.3 million(US$49.3 million) in China. As Shanghai Zhongxi Pharmaceutical Co., Ltd.’s hydroxychloroquine product has a certain price advantage, it has occupied a major share of the Chinese market. In 2019, based on sales value, Shanghai Zhongxi Pharmaceutical Co., Ltd.’s hydroxychloroquine accounted for 69% of the Chinese market.
As some studies have shown that hydroxychloroquine may have a certain effect on COVID-19, the demand for hydroxychloroquine in the global market will increase in 2020-2021. According to CRI’s market research, from January to August 2020, China’s exports of hydroxychloroquine increased by approximately 20% year-on-year. It is expected that China’s domestic hydroxychloroquine market sales will continue to grow from 2020 to 2024, and China’s hydroxychloroquine export value will also continue to rise.

Topics Covered:
– The impact of the COVD-19 epidemic on the hydroxychloroquine market
-Development environment of Chinese Hydroxychloroquine market
-Sales value and volume of Hydroxychloroquine in China 2015-2019
-Sales value and volume of Hydroxychloroquine in Different Regions of China 2015-2019
-Prices of Hydroxychloroquine in China 2015-2019
-Prices of Sanofi’s Hydroxychloroquine(Plaquenil) in Different Regions of China 2015-2019
-Prices of Shanghai Henlius Biotech, Inc.’s Hydroxychloroquine(Fenle) in Different Regions of China 2015-2019
-Progress of Generic Hydroxychloroquine in China
-Prospects of Chinese Hydroxychloroquine Market, 2020-2024

The post Investigation Report on Chinese Hydroxychloroquine(HCQ) Market, 2020-2024 first appeared on CRI Report.